Loading…
Royalty Transparency Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2026 · third_quarter · Medical/Disease Research/Clinical Labs
Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support efforts to ensure the National Institutes of Health (NIH) peer review system is not hampered. Issue: Avoid unnecessary restrictions on types of research including human embryonic stem cell, fetal tissue, gain of function, and animal research. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of National Institutes of Health (NIH)-supported medical research. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Provide comments on provisions to strengthen research, including rejecting inclusion of subtitle D, SAFE Research Act. S.5295 - NIH Mentorship Modernization Act Issue: Provide feedback on National Institutes of Health (NIH) research training and mentors. Issue: Suggest opportunities to strengthen support for clinical trials. Issue: Educate Congress and the administration on challenges associated with slow pace of National Institutes of Health (NIH) obligations.
Referred to the Committee on Oversight and Government Reform, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $431,446 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support efforts to ensure the National Institutes of Health (NIH) peer review system is not hampered. Issue: Avoid unnecessary restrictions on types of research including human embryonic stem cell, fetal tissue, gain of function, and animal research. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of NIH-supported medical research. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Provide comments on provisions to strengthen research, including rejecting inclusion of subtitle D, SAFE Research Act.
Client expense: $821,438 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2026 · first_quarter · Medical/Disease Research/Clinical Labs
Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support efforts to ensure the National Institutes of Health (NIH) peer review system is not hampered. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of NIH-supported medical research. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Provide comments on provisions to strengthen research, including rejecting inclusion of subtitle D, SAFE Research Act.
Client expense: $577,720 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2025 · fourth_quarter · Medical/Disease Research/Clinical Labs
Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support efforts to ensure the National Institutes of Health (NIH) peer review system is not hampered. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of NIH-supported medical research. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Provide comments on provisions to strengthen research, including rejecting inclusion of subtitle D, SAFE Research Act.
Client expense: $708,395 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2025 · third_quarter · Medical/Disease Research/Clinical Labs
Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Ensure bill does not hamper the National Institutes of Health (NIH) peer review system. H.Res.708 - Recognizing the contributions of medical research and observing "Medical Research Week" from September 15 through September 19, 2025. Issue: Educate Congress about the importance of NIH-supported medical research.
Client expense: $758,175 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2025 · second_quarter · Medical/Disease Research/Clinical Labs
Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). Issue: Provide input on proposed National Institutes of Health (NIH) optimization frameworks. H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support technical correction to ensure bill does not hamper the National Institutes of Health (NIH) peer review system.
Client expense: $831,429 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2025 · first_quarter · Medical/Disease Research/Clinical Labs
Issue: Educate Congress and the administration about the impact of regulatory burden on medical research. Issue: Oppose inappropriate use of march-in authority. Issue: Educate Congress and the administration about opportunities to strengthen medical research supported by National Institutes of Health (NIH). Issue: Provide input on proposed National Institutes of Health (NIH) optimization frameworks. H.R.1864/S.854 - Risky Research Review Act Issue: Support prevention of unintended consequences from new restrictions on life sciences research. H.R.1863/S.855 - Royalty Transparency Act Issue: Support technical correction to ensure bill does not paralyze National Institutes of Health (NIH) peer review system.
Client expense: $750,957 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office